Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02584634
Registration number
NCT02584634
Ethics application status
Date submitted
21/10/2015
Date registered
22/10/2015
Date last updated
7/07/2023
Titles & IDs
Public title
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)
Query!
Scientific title
A PHASE 1B/2, OPEN-LABEL, DOSE-FINDING STUDY TO EVALUATE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH EITHER CRIZOTINIB OR PF-06463922 IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Query!
Secondary ID [1]
0
0
2015-001879-43
Query!
Secondary ID [2]
0
0
B9991005
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non-Small Cell Lung Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Avelumab
Treatment: Drugs - PF-06463922
Treatment: Drugs - Crizotinib
Experimental: Group A - ALK negative Non-Small Cell Lung Cancer
Experimental: Group B - ALK positive Non-Small Cell Lung Cancer
Treatment: Drugs: Avelumab
Administered by IV once every two weeks in doses of either 5 mg/kg or 10 mg/kg
Treatment: Drugs: PF-06463922
Tablets taken orally once every day in doses of either 100mg, 75mg, or 50mg.
Treatment: Drugs: Crizotinib
Capsules. Taken orally once or twice every day in doses of either 200mg or 250mg.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Dose-limiting Toxicities (DLTs): Phase 1b
Query!
Assessment method [1]
0
0
Any of the following adverse events (AEs) occurring during the primary DLT observation period that are attributable to one, the other, or both study drugs were classified as DLTs: Grade 4 (life-threatening) neutropenia if >7 days in duration; febrile neutropenia; Grade >=3 (severe or life threatening) neutropenic infection; Grade >=3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia >7 days; Grade 4 anemia; any Grade >=3 toxicity, except for any of the following: transient (<=6 hours) Grade 3 (severe) flu like symptoms or fever; transient (<=24 hours) Grade 3 fatigue, local reactions, or headache that resolved to Grade <=1 (no AE or mild AE); Grade 3 nausea and/or vomiting, diarrhea or skin toxicity that resolved to Grade <=1 within 7 days; any Grade >=3 amylase or lipase abnormality; tumor flare phenomenon; single laboratory values out of normal range that were not related to treatment, did not have any clinical correlate, and resolve to Grade <=1 within 7 days.
Query!
Timepoint [1]
0
0
First 2 cycles (1 cycle = 14 days)
Query!
Primary outcome [2]
0
0
Percentage of Participants With Objective Response (OR): Phase 2
Query!
Assessment method [2]
0
0
OR is defined as complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 from start date (the date of first dose of study treatment) until disease progression or death due to any cause. Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met. Per RECIST v1.1: CR is defined as the disappearance of all target or non-target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to <10 mm and all lymph nodes must be non-pathological in size (<10 mm short axis). PR is defined as a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Query!
Timepoint [2]
0
0
Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)
Query!
Primary outcome [3]
0
0
Percentage of Participants With CR for Group B: Phase 2
Query!
Assessment method [3]
0
0
Per RECIST v1.1: CR is defined as the disappearance of all target or non-target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to <10 mm and all lymph nodes must be non-pathological in size (<10 mm short axis).
Query!
Timepoint [3]
0
0
Baseline up to 60 months
Query!
Secondary outcome [1]
0
0
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Query!
Assessment method [1]
0
0
TEAEs are those events with onset dates occurring during the on-treatment period for the first time, or if the worsening of an event is during the on-treatment period. Treatment-related AEs was any untoward medical occurrence attributed to study drug in a participant who received study drug. Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03: Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment; Grade 4 (Life-threatening) events caused participant to be in imminent danger of death; Grade 5 (Death) events=death related to an AE. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in participant hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Query!
Timepoint [1]
0
0
Baseline up to 30 days after last dose of study treatment or the day before start day of new anti-cancer therapy (maximum of 5 years)
Query!
Secondary outcome [2]
0
0
Number of Participants With Baseline Laboratory Abnormalities Grade <=2 and Post-Baseline Laboratory Abnormalities of Grades 3 or 4 Per NCI CTCAE v4.03
Query!
Assessment method [2]
0
0
The laboratory results were graded according to the NCI CTCAE v4.03 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE. Grade 4=life-threatening consequences; urgent intervention indicated. Shift tables were provided to examine the distribution of laboratory toxicities. The following parameters had met the criteria of CTCAE grade shift change from Grade <=2 at baseline to Grade 3 or 4 post baseline: anemia, lymphocyte count decreased, lymphocyte count decreased, neutrophil count decreased, white blood cell decreased, alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, cholesterol high, Creatine phosphokinase (CPK) increased, Gamma glutamyl transferase (GGT) increased, hypercalcemia, hyperglycemia, hypermagnesemia, hypertriglyceridemia, hypoalbuminemia, hyponatremia, lipase increased, serum amylase increased. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment.
Query!
Timepoint [2]
0
0
Screening up to end of treatment/withdrawal (maximum of 5 years)
Query!
Secondary outcome [3]
0
0
Number of Participants With Vital Signs Meeting Pre-defined Criteria
Query!
Assessment method [3]
0
0
Pre-defined criteria in vital signs: pulse rate <50 beats per minute, pulse rate >120 bpm, sitting diastolic blood pressure (DBP) increase and decrease in change from baseline of >= 20 millimeter of mercury (mmHg), sitting systolic blood pressure(SBP) < 90 mmHg, increase and decrease in change from baseline of >= 30mmHg. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment.
Query!
Timepoint [3]
0
0
Screening up to end of treatment/withdrawal (maximum of 5 years)
Query!
Secondary outcome [4]
0
0
Disease Control Rate (DCR)
Query!
Assessment method [4]
0
0
DC is defined as objective response (CR or PR) or stable disease (SD) per RECIST v.1.1 from the date of first dose of study treatment until disease progression or death due to any cause. The DCR is the proportion of patients with DC. Per RECIST v1.1: CR is defined as the disappearance of all target or non-target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to <10 mm. PR is defined as a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD is defined as a >=20% increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions.
Query!
Timepoint [4]
0
0
Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)
Query!
Secondary outcome [5]
0
0
Duration of Response (DR)
Query!
Assessment method [5]
0
0
DR: time from first documented occurrence of response (PR or CR) until date of first documented PD or death due to underlying cancer. Per RECIST 1.1: CR: disappearance of all non-nodal target lesions and of all non-target lesions; any pathological lymph nodes assigned as target lesions/non-target lesions have a reduction in short axis to <10 mm. PR: at least a >=30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters. PD: at least a >=20% increase in sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Appearance of new lesions. Participants with no PD and were still alive by 02 Feb 2020, were censored at last adequate tumor assessment. Kaplan-Meier method was used for DR analysis.
Query!
Timepoint [5]
0
0
Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)
Query!
Secondary outcome [6]
0
0
Time to Tumor Response (TTR)
Query!
Assessment method [6]
0
0
TTR is defined, for participants with an objective response (CR or PR), as the time from the start date (the date of first dose of treatment) to the first documentation of objective response (CR or PR) which is subsequently confirmed. Per RECIST v1.1: CR: disappearance of all non-nodal target lesions and of all non-target lesions. In addition, any pathological lymph nodes assigned as target lesions/ non-target lesions must have a reduction in short axis to <10 mm. PR: at least a 30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters.
Query!
Timepoint [6]
0
0
Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)
Query!
Secondary outcome [7]
0
0
Progression-free Survival (PFS)
Query!
Assessment method [7]
0
0
PFS is defined as the time from start date (the date of first dose of treatment) to the date of the first documentation of PD per RECIST v1.1 or death due to any cause, whichever occurs first. Per RECIST v1.1: PD: a >=20% increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Query!
Timepoint [7]
0
0
Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)
Query!
Secondary outcome [8]
0
0
Kaplan-Meier Estimates of Overall Survival (OS)
Query!
Assessment method [8]
0
0
OS is defined as the time from start date (the date of first dose of treatment) to the date of death due to any cause.
Query!
Timepoint [8]
0
0
Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)
Query!
Secondary outcome [9]
0
0
Maximum Plasma Concentration (Cmax) of Crizotinib in The Presence of Avelumab
Query!
Assessment method [9]
0
0
Cmax of crizotinib in the presence of avelumab was observed directly from data.
Query!
Timepoint [9]
0
0
Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Query!
Secondary outcome [10]
0
0
Time to Cmax (Tmax) of Crizotinib in The Presence of Avelumab
Query!
Assessment method [10]
0
0
Tmax of crizotinib in the presence of avelumab was observed directly from data as time of first occurrence.
Query!
Timepoint [10]
0
0
Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Query!
Secondary outcome [11]
0
0
Area Under The Plasma Concentration-Time Curve During The Dosing Interval Time Course (AUCtau) of Crizotinib in The Presence of Avelumab
Query!
Assessment method [11]
0
0
AUCtau of crizotinib in the presence of avelumab was calculated by Linear/Log trapezoidal method. Dose interval is defined as after single dose from time zero to the next dose (after single dose and at steady state).
Query!
Timepoint [11]
0
0
Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Query!
Secondary outcome [12]
0
0
Apparent Plasma Clearance (CL/F) of Crizotinib in The Presence of Avelumab
Query!
Assessment method [12]
0
0
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Query!
Timepoint [12]
0
0
Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Query!
Secondary outcome [13]
0
0
Cmax of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab
Query!
Assessment method [13]
0
0
Cmax of crizotinib metabolite PF-06260182 in the presence of avelumab was observed directly from data.
Query!
Timepoint [13]
0
0
Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Query!
Secondary outcome [14]
0
0
Tmax of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab
Query!
Assessment method [14]
0
0
Tmax of crizotinib metabolite PF-06260182 in the presence of avelumab was observed directly from data as time of first occurrence.
Query!
Timepoint [14]
0
0
Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Query!
Secondary outcome [15]
0
0
AUCtau of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab
Query!
Assessment method [15]
0
0
AUCtau of crizotinib metabolite PF-06260182 in the presence of avelumab was calculated by Linear/Log trapezoidal method. Dose interval: single dose from time zero to the next dose (after single dose and at steady state).
Query!
Timepoint [15]
0
0
Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Query!
Secondary outcome [16]
0
0
Metabolite to Parent Ratio for AUCtau (MRAUCtau) of PF-06260182 in The Presence of Avelumab
Query!
Assessment method [16]
0
0
MRAUCtau of metabolite PF-06260182 in the presence of avelumab was calculated (MRAUCtau=Metabolite AUCtau/parent AUCtau). Parent=crizotinib, metabolite=PF-06260182
Query!
Timepoint [16]
0
0
Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Query!
Secondary outcome [17]
0
0
Metabolite to Parent Ratio for Cmax (MRCmax) of PF-06260182 in The Presence of Avelumab
Query!
Assessment method [17]
0
0
MRCmax of metabolite PF-06260182 in the presence of avelumab was calculated (MRCmax=Metabolite Cmax/parent Cmax). Parent=crizotinib, metabolite=PF-06260182
Query!
Timepoint [17]
0
0
Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Query!
Secondary outcome [18]
0
0
Cmax of Lorlatinib in The Presence of Avelumab
Query!
Assessment method [18]
0
0
Cmax of lorlatinib in the presence of avelumab was observed directly from data.
Query!
Timepoint [18]
0
0
Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2
Query!
Secondary outcome [19]
0
0
Tmax of Lorlatinib in The Presence of Avelumab
Query!
Assessment method [19]
0
0
Tmax of lorlatinib in the presence of avelumab was observed directly from data.
Query!
Timepoint [19]
0
0
Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2
Query!
Secondary outcome [20]
0
0
AUCtau of Lorlatinib in The Presence of Avelumab
Query!
Assessment method [20]
0
0
AUCtau of lorlatinib in the presence of avelumab was calculated by Linear/Log trapezoidal method. Dose interval: single dose from time zero to the next dose (after single dose and at steady state).
Query!
Timepoint [20]
0
0
Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2
Query!
Secondary outcome [21]
0
0
Area Under The Plasma Concentration Time Curve From Time of Dosing to The Last Collection Time Point (AUClast) of Lorlatinib in The Presence of Avelumab
Query!
Assessment method [21]
0
0
AUClast of lorlatinib in the presence of avelumab.
Query!
Timepoint [21]
0
0
Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2
Query!
Secondary outcome [22]
0
0
CL/F of Lorlatinib in The Presence of Avelumab
Query!
Assessment method [22]
0
0
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Query!
Timepoint [22]
0
0
Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2
Query!
Secondary outcome [23]
0
0
Cmax of Avelumab in The Presence of Crizotinib (Group A) or Lorlatinib (Group B) After Single Dose of Avelumab
Query!
Assessment method [23]
0
0
Cmax of avelumab in the presence of crizotinib was observed directly from the data in Group A. Cmax of avelumab in the presence of lorlatinib was observed directly from the data in Group B.
Query!
Timepoint [23]
0
0
Pre-dose, 1, and 168 hours post dose of avelumab on Cycle 1 Day 1.
Query!
Secondary outcome [24]
0
0
Cmax of Avelumab in The Presence of Crizotinib (Group A) or Lorlatinib (Group B) After Multiple Doses of Avelumab
Query!
Assessment method [24]
0
0
Cmax of avelumab in the presence of crizotinib was observed directly from the data in Group A. Cmax of avelumab in the presence of lorlatinib was observed directly from the data in Group B.
Query!
Timepoint [24]
0
0
Pre-dose, 1, and 168 hours post dose of avelumab on Cycle 2 Day 1
Query!
Secondary outcome [25]
0
0
Trough Serum Concentration (Ctrough) of Avelumab in The Presence of Crizotinib (Group A) Following Multiple Doses of Avelumab
Query!
Assessment method [25]
0
0
Ctrough is defined as predose concentration following multiple doses. Ctrough of avelumab in the presence of crizotinib was observed directly from the data in Group A.
Query!
Timepoint [25]
0
0
Pre-dose on Day 1 of Cycles 2-5, 11, 17, 23, 29, 35, and 47.
Query!
Secondary outcome [26]
0
0
Trough Serum Concentration (Ctrough) of Avelumab in The Presence of Lorlatinib (Group B) Following Multiple Doses of Avelumab
Query!
Assessment method [26]
0
0
Ctrough is defined as predose concentration following multiple doses. Ctrough of avelumab in the presence of lorlatinib was observed directly from the data in Group B.
Query!
Timepoint [26]
0
0
Pre-dose on Day 1 of Cycles 2-5, 11, 17, 23, 29, 35, 41, and 47.
Query!
Secondary outcome [27]
0
0
Number of Participants With Anti-Drug Antibodies (ADA) Against Avelumab by Never and Ever Positive Status
Query!
Assessment method [27]
0
0
ADA never-positive was defined as no positive ADA results at any time point. ADA ever-positive was defined as at least one positive ADA result at any time point. Baseline is defined as the last assessment on or prior to the date/time of the first dose of avelumab.
Query!
Timepoint [27]
0
0
Day 1 of Cycles 1-5, then every 12 weeks thereafter, end of treatment/withdrawal, and 30 days after last avelumab dose (up to a maximum of 5 years)
Query!
Secondary outcome [28]
0
0
Number of Participants With Positive Programmed Death Ligand-1 (PD-L1) Biomarker Expression
Query!
Assessment method [28]
0
0
PD-L1 protein expression is determined by using Combined Positive Score (CPS), which is the percentage of viable tumor and tumor-infiltrated immune cells (restricted to lymphocytes and macrophages) within or directly associated with tumor cell strands showing partial or complete membrane staining using the SP263 antibody. Positive is defined as CPS>=1% and negative is defined as CPS <1%.
Query!
Timepoint [28]
0
0
Baseline
Query!
Secondary outcome [29]
0
0
Number of Participants With Positive Tumor Infiltrating CD8+ Lymphocytes
Query!
Assessment method [29]
0
0
Tumor infiltrating CD8+ lymphocytes is defined as the number of CD8+ cells per unit area and the percent of counted cells. Positive is defined as >=1% and negative is defined as <1%.
Query!
Timepoint [29]
0
0
Baseline
Query!
Eligibility
Key inclusion criteria
- Inclusion Criteria
- Diagnosis of advanced or metastatic NSCLC. Group A must be ALK negative NSCLC and
Group B must be ALK positive NSCLC
- Group A at least one prior regimen of therapy
- Group B any number of prior regimens.
- Mandatory tumor tissue available
- At least one measurable lesion
- ECOG Performance status 0 or 1
- Adequate bone marrow, renal, liver and pancreatic function
- Negative pregnancy test for females of childbearing potential
- Group B Phase 2: No prior systemic treatment for advanced or metastatic disease
(adjuvant and/or neoadjuvant therapies are allowed if completed at least 6 months
prior to study entry. No prior tyrosine kinase inhibitor therapy is allowed at any
time prior to study entry)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- No prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4
antibody.
- No Severe or Chronic medical conditions including gastrointestinal abnormalities or
significant cardiac history
- No active infection requiring systemic therapy
- Prior organ transplantation including allogenic stem cell transplantation.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
18/12/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
13/07/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
43
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Chris O'Brien Lifehouse - Camperdown
Query!
Recruitment hospital [2]
0
0
The Prince Charles Hospital - Chermside
Query!
Recruitment hospital [3]
0
0
Peter MacCallum Cancer Centre - Melbourne
Query!
Recruitment hospital [4]
0
0
Royal Melbourne Hospital - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
4032 - Chermside
Query!
Recruitment postcode(s) [3]
0
0
3000 - Melbourne
Query!
Recruitment postcode(s) [4]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Georgia
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Massachusetts
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Tennessee
Query!
Country [4]
0
0
Japan
Query!
State/province [4]
0
0
Aichi
Query!
Country [5]
0
0
Japan
Query!
State/province [5]
0
0
Fukuoka
Query!
Country [6]
0
0
Japan
Query!
State/province [6]
0
0
Koto-ku, Tokyo
Query!
Country [7]
0
0
Korea, Republic of
Query!
State/province [7]
0
0
Gyeonggi-do
Query!
Country [8]
0
0
Korea, Republic of
Query!
State/province [8]
0
0
Seoul
Query!
Country [9]
0
0
Spain
Query!
State/province [9]
0
0
Barcelona
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the safety and efficacy of avelumab when combined
with either crizotinib or PF-06463922.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02584634
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02584634
Download to PDF